New York, NY -- (SBWIRE) -- 12/18/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), ON Semiconductor Corp (NASDAQ:ONNN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), MannKind Corporation (NASDAQ:MNKD)
Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) showed a volume of 2.87 million shares by the end of last trade whereas the average volume of the stock remained 2.88 million shares. The stock opened the session at $7.84 but then moved to $7.71. At that price, the stock showed a negative performance of -0.52%. Companhia Energetica de Minas Gerais Cemig is a Brazil-based holding company primarily engaged in the electricity sector. The Company is mainly active in the construction and operation of systems of production, transformation, transmission, distribution and commercialization of electric power. It is involved in the provision of telecommunication services, and purchase, transport and distribution of natural gas.
Will CIG Get Buyers Even After The Recent Rally? Find Out Here
ON Semiconductor Corp (NASDAQ:ONNN) opened the session at $7.60 and closed the session at $7.67. The stock showed a positive performance of 0.79% in previous trading session. Traded with volume of 2.87 million shares in the prior session and the average volume of the stock remained 5.15 million shares. ON Semiconductor Corporation (ON Semiconductor) designs, manufactures and markets a portfolio of semiconductor components that address the design needs of electronic systems and products. The Company operates in three segments: Application Products Group, Standard Products Group, and SANYO Semiconductor Products Group. The Company's power management semiconductor components control, convert, protect and monitor the supply of power to the different elements within a variety of electronic devices. The Company’s portfolio of power and signal management, logic, discrete and custom devices focuses customers in automotive, communications, computing, consumer,
For How Long ONNN will fight for Profitability? Read This Trend Analysis report
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) opened the session at $4.44 and closed the session at $5.24. The stock showed a positive performance of 17.75% in previous trading session. Traded with volume of 2.85 million shares in the prior session and the average volume of the stock remained 803,221.00 shares. The beta of the stock remained 0.43. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719.
Why Should Investors Buy IDIX After The Recent Gain? Just Go Here and Find Out
MannKind Corporation (NASDAQ:MNKD) the stock decreased -0.42% and finished the session at $4.94. Traded with volume of 2.83 million shares in the prior session and the average volume of the stock remained 4.44 million shares. The beta of the stock remained 1.87. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company’s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules.
Will MNKD Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)